Patent classifications
C
CHEMISTRY; METALLURGY
Load children
C12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Load children
C12Y
ENZYMES
Load children
306/00
Hydrolases acting on acid anhydrides (3.6)
Load children Filter patents View analytics View as hierarchy Open in page
C12Y306/01
in phosphorus-containing anhydrides (3.6.1)
Load children Filter patents View analytics View as hierarchy Open in page
C12Y306/01029
Bis(5'-adenosyl)-triphosphatase (3.6.1.29)
Filter patents View analytics View as hierarchy Open in page

C12Y306/01029

COMPOSITIONS FOR TREATING PATHOLOGICAL CALCIFICATION CONDITIONS, AND METHODS USING SAME
20210401950 · 2021-12-30 ·

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of ENPP4.

Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension
11413280 · 2022-08-16 · ·

The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.

Compositions and methods for treating nonsteroidal anti-inflammatory drug (NSAID) associated coagulopathy, thrombocytopenia, glanzmann's thrombasthenia, and/or thrombosis
11123408 · 2021-09-21 · ·

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of ENPP4.

ENZASTAURIN AND FRAGILE HISTIDINE TRIAD (FHIT)-INCREASING AGENTS FOR THE TREATMENT OF PULMONARY HYPERTENSION
20200206214 · 2020-07-02 ·

The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.

COMPOSITIONS AND METHODS FOR TREATING NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) ASSOCIATED COAGULOPATHY, THROMBOCYTOPENIA, GLANZMANN'S THROMBASTHENIA, AND/OR THROMBOSIS
20190167768 · 2019-06-06 ·

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of ENPP4.

Compositions and methods for treating platelet storage pool deficiency, gray platelet syndrome and quebec platelet disorder
10258671 · 2019-04-16 · ·

The present invention relates to compositions and methods for treating diseases of coagulation using a NPP4 polypeptide.

Compositions and Methods for Modulating Coagulation
20180169192 · 2018-06-21 ·

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.

Compositions and methods for treating hemophilia
09867870 · 2018-01-16 · ·

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.

Compositions and Methods for Modulating Coagulation
20170274054 · 2017-09-28 ·

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.

Compositions and methods for modulating coagulation
09642896 · 2017-05-09 · ·

The present invention relates to compositions and methods for modulating coagulation through modulating the level or activity of NPP4.